Other languages Suven Life Sciences Limited

Equities

SUVEN

INE495B01038

Delayed Bombay S.E. Other stock markets 01:22:35 06/05/2024 pm IST			5-day change	1st Jan Change
111.5 ^INR	-1.72%		-0.17%	+38.23%

15/04	Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	CI
06/02	Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	15/04
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	06/02
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024	30/01
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	30/01
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	04/11
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy	30/23/30
Suven Pharma Appoints New Board and Management Team	30/23/30
Suven Pharma Appoints Sudhir Kumar Singh as CEO	30/23/30
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/23/08
Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada	01/23/01
Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2023	09/23/09
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	09/23/09
Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type	16/22/16
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/22/10
Suven Pharmaceuticals' Consolidated Net Profit Declines in Fiscal Q2	08/22/08
Suven Life Sciences Gets Board Panel Nod for Rights Issue	14/22/14
Suven Pharmaceuticals Board Declares Interim Dividend and Special Dividend for Fiscal 2023	02/22/02
Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022	02/22/02
Suven Pharmaceuticals Mulls Interim Dividend for Fiscal 2023	29/22/29
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	26/22/26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Suven Life Sciences Limited

Equities

SUVEN

INE495B01038

Other languages

Filters